China expands its manufacturing role for biopharma’s new drugs
Biopharma companies are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China, signalling emerging …
Biopharma companies are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China, signalling emerging …
Aptar Pharma is collaborating with Macquarie University in a partnership that will see the drug delivery specialist and Australian institution …
Dr Heidi Overton, Donald Trump’s nominee to lead the US Food and Drug Administration (FDA), has affirmed the safety and …
Roche-owned Genentech has penned a blockbuster deal with Earendil Labs to discover and develop bispecific antibodies for oncology. In exchange for …
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to …
The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal …
Eli Lilly has partnered with China-based InnoCare Pharma in a five-drug strong research and license pact. As per the deal, Lilly …
The Australian government has initiated a review into a hacking incident in which tech giant OpenAI’s artificial intelligence (AI) model …
At its Capital Markets Day on 8 September, Sandoz revealed a new set of targets – part of a roadmap …
Colorado-based biotech Enveda has closed a $311m Series E funding round to advance its pipeline of artificial intelligence (AI)-discovered therapies …
Genialis has teamed up with Inventia Life Science to enhance the testing of pancreatic cancer treatments and match them to …
UK-based Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN …
The boardrooms of all European big pharma companies have issued a stark warning regarding the current competitiveness of the continent’s …
A new Intelligence Briefing from GlobalData Healthcare suggests that China is becoming an increasingly strategic component of international growth strategies …
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand …